Insilco new aspects of peptide-based vaccine designing for human papilloma virus infection

To strength the potency of vaccines against infectious diseases, vaccines should be able to activate multiple arms of the immune system including innate and adaptive immunity. Moreover, genetic variation often occurs in infectious microorganisms can reduce the effectiveness of vaccines. Current vaccines and methods to immunisation against human papilloma virus, as a leading cause of different cancers, stimulate immune system moderately. In this study, to obtain highly effective responses, conserved Th and B-cell epitopes of L1 and CTL and Th epitopes of E7 are fused to helicobacter pylori NapA which is responsible for activation of innate immunity and direction favourable response to appropriate state. Finding the best conserved epitopes in order to induce better immune system may increase promising approach to achieve high-level immunity against infectious agents such as human papilloma virus (HPV). Thus, elevated immunity can be able to eradicate HPV vigorously. Designed construct can be useful as a peptide-based subunit vaccine to confer both preventive and therapeutic effects against all HPV16 subtypes.